Is Bliss GVS Pharma Ltd (BLISSGVS) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a average quality company .

Is Bliss GVS Pharma Ltd (BLISSGVS) undervalued or overvalued?

The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Bliss GVS Pharma Ltd (BLISSGVS) share price return in the past 10 years?

Bliss GVS Pharma Ltd share price has appreciated 7.3% annually (CAGR) over the past ten years.

Is Bliss GVS Pharma Ltd (BLISSGVS) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Bliss GVS Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Bliss GVS Pharma Ltd (BLISSGVS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Bliss GVS Pharma Ltd (BLISSGVS) on 17-Apr-2026 16:59:59 at 16:59 is 258.35.

What is the P/E ratio of Bliss GVS Pharma?

The latest standalone P/E ratio of Bliss GVS Pharma as of 17-Apr-2026 is 36.01.

What is the P/B ratio of Bliss GVS Pharma Ltd (BLISSGVS)?

The latest standalone P/B ratio of Bliss GVS Pharma Ltd (BLISSGVS) as of 17-Apr-2026 is 2.44.

What is the 52-week high and low of Bliss GVS Pharma Ltd (BLISSGVS)?

The 52-week high of Bliss GVS Pharma Ltd (BLISSGVS) is Rs. 267.15 and the 52-week low is Rs. 105.05.

Bliss GVS Pharma Ltd (BLISSGVS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Bliss GVS Pharma Ltd (BLISSGVS)
Brand: Bliss GVS Pharma

Bliss GVS Pharma Ltd (BLISSGVS) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Bliss GVS Pharma Ltd (BLISSGVS)

BSE: 506197 NSE: BLISSGVS

Key Metrics

Market Cap

₹2,733 Cr.

P/E Ratio

36.01

Price to Book (P/B)

2.44

Price to Sales (P/S)

4.05

EV/EBITDA

17.82

Return on Capital Employed (ROCE)

9.31%

Current Price

₹258.4

Return on Equity (ROE)

6.78%

Return on Assets (ROA)

5.85%

Operating Profit Margin

13.8%

Net Profit Margin

10.34%

Gross Profit Margin

18.2%

Book Value per Share

₹106.1

Sales Growth (YoY)

10.2%

Sales Growth (3 Years)

1.59%

Operating Profit Growth (1 Year)

-14.54%

Operating Profit Growth (3 Years)

-5.69%

Net Profit Growth (1 Year)

36.2%

52-Week Low / High

₹105 / 267

Net Profit Growth (3 Years)

-9.38%

Dividend Yield

0.43%

Promoter Holding

35.36%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Bliss GVS Pharma Ltd?

Bliss GVS Pharma Ltd revenue growth is 10.2% for FY-2025 , which is above its 5 year CAGR of 8.6% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Bliss GVS Pharma Ltd?

Promoters hold 35.36% of the Bliss GVS Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Bliss GVS Pharma Ltd vs industry peers?

Bliss GVS Pharma Ltd revenue CAGR is 8.59% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Bliss GVS Pharma Ltd belong to?

Bliss GVS Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Bliss GVS Pharma Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 6.6% based on the current price.

DeciZen - make an informed investing decision on Bliss GVS Pharma

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Bliss GVS Pharma stock performance

Key Ratios

Is Bliss GVS Pharma Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	23.4%	19.3%	15.6%	18.8%	17.8%	12%	14.7%	12.9%	7.4%	9.3%	-
Value Creation Index ⓘ	0.7	0.4	0.1	0.3	0.3	-0.1	0.1	-0.1	-0.5	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	326	348	298	427	442	466	636	598	605	667	674
Sales YoY Gr.	-	6.6%	-14.4%	43.2%	3.6%	5.3%	36.7%	-6%	1.2%	10.2%	-
Adj EPS ⓘ	5.4	5.8	5.2	5.4	7	6	7.5	5.6	6.6	5.2	7.2
YoY Gr.	-	6.9%	-10.8%	4.3%	29.6%	-13.2%	23.3%	-24.7%	16.8%	-20%	-
BVPS (₹) ⓘ	41.9	47.7	52.5	58.5	66.2	72.3	81.2	89.1	93.7	99.9	106.1
Adj Net Profit ⓘ	55.7	59.5	53.2	55.3	71.8	62.3	77.3	58.4	68.6	55.2	76
Cash Flow from Ops. ⓘ	59.6	38.5	22.7	48.3	63.2	67	114	43.8	82.2	97.2	-
Debt/CF from Ops. ⓘ	1.4	2	4.1	1.5	1.4	1.3	0.8	1.8	0.8	0.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.3%	8.6%	1.6%	10.2%
Adj EPS ⓘ	-0.3%	-5.5%	-11.1%	-20%
BVPSⓘ	10.1%	8.6%	7.2%	6.6%
Share Price	7.3%	21.8%	51%	106.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	13.9	12.9	10.3	9.7	11.2	8.7	9.6	6.5	7.1	5.4	7
Op. Profit Mgn % ⓘ	29.6	29	29.7	22.4	22.7	19.7	17.2	15.1	17.7	13.8	13.6
Net Profit Mgn % ⓘ	17.1	17.1	17.9	13	16.2	13.4	12.1	9.8	11.3	8.3	11.3
Debt to Equity ⓘ	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	-
Working Cap Days ⓘ	527	533	621	442	443	471	372	419	400	342	207
Cash Conv. Cycle ⓘ	206	206	270	269	307	293	212	233	242	236	168

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	7.2	10.3
TTM Sales (₹ Cr.)	674	868
BVPS (₹) ⓘ	106.1	109.4
Reserves (₹ Cr.) ⓘ	1,112	1,147
P/BV ⓘ	2.44	2.36
PE ⓘ	36.01	25.05

From the Market
52 Week Low / High (₹)	105.05 / 267.15
All Time Low / High (₹)	0.04 / 267.15
Market Cap (₹ Cr.)	2,733
Equity (₹ Cr.)	10.6
Face Value (₹)	1
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Bliss GVS Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	326	348	298	427	442	466	636	598	605	667
Operating Expenses ⓘ +	230	247	209	333	342	374	527	508	498	576
Manufacturing Costs	27	6	6	8	11	14	18	17	26	25
Material Costs	114	167	146	225	237	253	344	315	299	346
Employee Cost	22	25	26	34	44	59	65	73	83	99
Other Costs ⓘ	67	49	31	67	50	48	100	104	90	105
Operating Profit ⓘ	97	101	88	93	100	91	109	90	107	92
Operating Profit Margin (%)	29.6%	28.9%	29.7%	21.8%	22.7%	19.6%	17.2%	15.1%	17.7%	13.7%
Other Income ⓘ +	23	9	11	36	37	19	33	51	34	36
Exceptional Items ⓘ	0	0	0	0	0	0	3	0	-41	0
Interest ⓘ	14	9	7	3	7	6	4	10	6	7
Depreciation ⓘ	6	6	6	6	9	14	14	15	24	27
Profit Before Tax ⓘ	100	95	87	120	122	91	126	116	70	94
Tax ⓘ	35	36	30	46	29	24	34	30	20	25
Profit After Tax	66	59	57	74	92	68	93	85	51	69
PAT Margin (%)	20.1%	17.0%	19.1%	17.5%	20.9%	14.5%	14.6%	14.3%	8.4%	10.3%
Adjusted EPS (₹)	6.4	5.7	5.5	7.2	9.0	6.5	8.9	8.2	4.8	6.6
Dividend Payout Ratio (%)	8%	10%	18%	14%	6%	8%	6%	6%	10%	8%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	432	492	541	603	683	746	841	928	981	1,052
Share Capital ⓘ	10	10	10	10	10	10	10	10	10	11
Reserves ⓘ	422	481	531	593	673	735	831	918	970	1,042
Debt +	62	74	88	67	71	68	65	66	46	23
Long Term Debt	12	12	6	31	36	32	23	41	35	20
Short Term Debt	50	61	83	37	36	35	41	25	11	3
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	35	64	35	31	56	67	84	76	54	60
Others Liabilities ⓘ	168	37	29	35	45	65	90	70	65	75
Total Liabilities ⓘ	697	666	694	736	855	946	1,080	1,140	1,146	1,211
Fixed Assets
Net Fixed Assets ⓘ +	79	75	72	78	179	174	224	325	330	368
Gross Block	123	81	83	93	202	211	270	385	413	478
Accumulated Depreciation	44	6	11	15	23	37	45	60	84	110
CWIP ⓘ	2	2	0	43	0	2	22	3	8	21
Investments ⓘ	21	22	19	19	19	18	18	18	19	19
Inventories	22	28	40	55	61	84	90	74	89	82
Trade Receivables	251	239	283	342	405	349	409	399	400	428
Cash Equivalents	57	84	70	93	87	120	149	85	169	171
Others Assets ⓘ	266	216	209	105	105	199	167	236	131	122
Total Assets ⓘ	697	666	694	736	855	946	1,080	1,140	1,146	1,211

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	60	38	23	48	63	67	114	44	82	97
PBT ⓘ	100	95	87	120	122	91	124	116	111	94
Adjustment ⓘ	7	28	1	3	3	41	35	41	44	56
Changes in Working Capital ⓘ	-28	-47	-29	-26	-30	-43	-14	-76	-44	-23
Tax Paid ⓘ	-20	-37	-36	-50	-32	-23	-30	-38	-29	-30
Cash Flow From Investing Activity ⓘ +	-10	-29	16	-68	-60	-62	-92	-13	-66	-78
Capex	-5	-3	-1	-59	-67	-8	-73	-94	-38	-67
Net Investments	-1	-32	3	0	0	0	3	0	44	-16
Others ⓘ	-3	5	14	-9	7	-54	-22	81	-71	5
Cash Flow From Financing Activity ⓘ +	-35	-15	-22	9	-6	-12	-13	-26	-21	-27
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	2	2	2	3
Net Proceeds from Borrowing ⓘ	0	0	0	24	13	2	-5	-16	-10	-15
Interest Paid ⓘ	-11	-9	-8	-3	-4	-6	-2	-6	-5	-5
Dividend Paid ⓘ	-6	-5	-6	-12	-12	-6	-5	-5	-5	-5
Others ⓘ	-18	-0	-8	0	-2	-2	-2	-1	-3	-4
Net Cash Flow ⓘ	14	-6	17	-11	-3	-6	9	5	-4	-7

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	16.41	12.8	11.04	13	14.36	9.45	11.68	9.66	5.31	6.78
ROCE (%)	23.43	19.25	15.6	18.8	17.75	12.02	14.68	12.89	7.36	9.31
Asset Turnover Ratio	0.52	0.51	0.44	0.6	0.56	0.52	0.63	0.54	0.53	0.57
PAT to CFO Conversion(x)	0.91	0.64	0.4	0.65	0.68	0.99	1.23	0.52	1.61	1.41
Working Capital Days
Receivable Days	257	255	319	267	308	295	217	246	241	226
Inventory Days	25	26	42	40	48	57	50	50	49	47
Payable Days	136	108	124	54	67	88	80	93	79	61

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bliss GVS Pharma Ltd FAQs

The current trading price of Bliss GVS Pharma on 17-Apr-2026 16:59 is ₹258.4.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Bliss GVS Pharma stood at ₹2,733.1 Cr

The latest P/E ratio of Bliss GVS Pharma as of 16-Apr-2026 is 36.01.

The latest P/B ratio of Bliss GVS Pharma as of 16-Apr-2026 is 2.44.

The 52-week high of Bliss GVS Pharma is ₹267.1 and the 52-week low is ₹105.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bliss GVS Pharma is ₹674 ( Cr.) .

About Bliss GVS Pharma Ltd

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
2011: EU-GMP approval to the manufacturing facility for suppository facility.
2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
2017: Setting up offices in South East Asian countries.
2018: Divestment from Bliss GVS Healthcare.
2019: Setting up of multi-dosage facility (Vevoor Plant).

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Bliss GVS Pharma Ltd (BLISSGVS) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Bliss GVS Pharma Share Price